22 Aug 2026

CRC Research Update — August 22, 2026

Creator: The CRC Digest
Published: 2026-08-22T20:15:31Z

Today's colorectal cancer research highlights

1 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

SCREENING
Inadequate bowel prep obscures polyps and early cancer signs, increases costs
A new guideline emphasizes that inadequate bowel preparation can obscure polyps, lesions, or early signs of colorectal cancer while increasing procedure length and shortening surveillance intervals; experts recommend aiming for adequate prep in over 90% of colonoscopies. (Aliment Pharmacol Ther)
RESEARCH
ctDNA methylation profiling may predict prognosis beyond mutation testing
DNA methylation in circulating tumor DNA may provide additional prognostic information beyond mutation-based analysis by reflecting coordinated regulatory states associated with tumor behavior, including transcriptional programs and cellular plasticity. (Epigenomics)
TREATMENT
Prophylactic HIPEC analyzed for survival outcomes in locally advanced colorectal cancer
A meta-analysis of 2,023 patients analyzed prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced colorectal cancer, extracting and pooling data to analyze peritoneal metastasis-free survival, disease-free survival, and overall survival. (Ann Surg Oncol)
RESEARCH
New ctDNA assay validated for minimal residual disease monitoring across solid tumors
The Haystack MRD assay, a tumor-informed ctDNA test that tracks patient-specific somatic mutations, has been analytically and clinically validated across 23 solid tumor types for detecting minimal residual disease at low abundance. (J Mol Diagn)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

HER2 amplification studied in resectable CRC
A study of 3,607 patients with resectable colorectal cancer investigated the prognostic impact of WES-defined ERBB2 amplification and its association with adjuvant chemotherapy efficacy and circulating tumor DNA. (Int J Clin Oncol)
Disrupting KRAS-AGO2 interaction may sensitize KRAS-mutant CRC to therapy
Preclinical research developed peptide-gold nanoparticles that disrupt the interaction between mutated KRAS and AGO2, potentially sensitizing KRAS-mutated colorectal cancer to chemo-immunotherapy. (Apoptosis)

Research continues to refine how we detect, monitor, and treat colorectal cancer at every stage.

Get CRC research intelligence delivered weekly — free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues

CRC Research Update

Subscribe to The CRC Digest